Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cyclo Therapeutics, Inc. (CTDH)
|
Add to portfolio |
|
|
|
| Price: |
$4.30
| | Metrics |
| OS: |
19.3
|
M
| |
|
|
| Market cap: |
$83
|
M
| |
|
|
|
Net cash:
|
$841.5
|
k
| |
$0.04
|
per share
|
|
EV:
|
$82.2
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($18.9)
|
M
| |
|
|
|
EBIT
|
($18.9)
|
M
| |
|
|
| EPS |
($1.88)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 1.4 | 1.6 | 0.9 | 1.0 | 1.0 | 1.2 | 1.5 | 1.0 |
| Revenue growth | -13.2% | 75.5% | -10.3% | -0.4% | -18.3% | -17.6% | 58.1% | -39.4% |
| Cost of goods sold | 4.1 | 4.0 | 2.6 | 2.0 | 1.3 | 1.3 | 1.5 | 1.1 |
| Gross profit | -2.7 | -2.4 | -1.7 | -1.0 | -0.3 | -0.1 | 0.0 | -0.1 |
| Gross margin | -198.6% | -151.9% | -190.9% | -96.8% | -26.2% | -6.4% | -0.1% | -12.9% |
| Selling, general and administrative | 3.4 | 2.5 | 1.0 | 1.4 | 1.2 | 1.3 | 1.2 | 0.8 |
| Research and development | 9.0 | 9.2 | 6.1 | 4.9 | 2.7 | 2.3 | 1.9 | 0.7 |
| General and administrative | 2.4 | 1.5 | 0.5 | 0.6 | 0.8 | 0.9 | 0.6 | 0.5 |
| EBIT | -15.6 | -14.3 | -9.0 | -7.5 | -4.3 | -3.8 | -3.3 | -2.3 |
| EBIT margin | -1135.5% | -901.2% | -992.0% | -749.1% | -421.8% | -310.7% | -222.7% | -240.1% |
| Pre-tax income | -15.5 | -14.3 | -8.9 | -7.5 | -4.3 | -3.8 | -4.2 | -2.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | -15.5 | -14.3 | -8.9 | -7.5 | -4.3 | -3.8 | -4.2 | -2.6 |
| Net margin | -1123.1% | -900.9% | -989.8% | -747.9% | -420.7% | -309.7% | -281.0% | -268.4% |
| |
| Diluted EPS | ($1.83) | ($2.24) | ($5.59) | ($6.96) | ($0.05) | ($0.05) | ($0.07) | ($0.05) |
| Shares outstanding (diluted) | 8.4 | 6.4 | 1.6 | 1.1 | 81.8 | 72.0 | 63.4 | 56.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|